Novartis has been on an investment spree this year. With almost USD 500 million invested in 7 companies, the company is making some high bets. Some of the key areas wherein the company has invested in are:  Cell and Gene Therapies  DNA Replication Targeting Drugs  Cancer Diagnosis  Virtual Clinical Trials The companies that they have invested in include - Freenome, Science 37, IMMPACT BIO USA INC, GentiBio, FoRx Therapeutics, Akouos, TScan Therapeutics.

1. INVESTMENTS
498 MILLION
2020
7

2. LET'S LOOK AT THE
NUMBERS.....
Series C
54.2%
Series B
28.1%
Others
8%
Seed
6% Series A
3.6%
Seed
Series
A
Series
B
Series
C
O
thers
2
1.5
1
0.5
0
Distribution by Number of Instances
Distribution by Funding Amount

3. Cell and Gene Therapy
57.1%
Virtual Clinical Trials
14.3%
Cancer Diagnosis
14.3%
DNA Replication Targeting Drugs
14.3%
The company appears to be
going all in on cell and gene
therapies
FOCUS AREA OF THE
COMPANIES...

4. THE COMPANY IS
CONNECTING PEOPLE
WITH NEXT-
GENERATION BLOOD
TESTS FOR EARLY
CANCER DETECTION
POWERED BY ITS
MULTIOMICS
PLATFORM
LET'S LOOK AT THE
COMPANIES.....

5. THE PLATFORM
IS THE INDUSTRY’S
FIRST AND ONLY
COMPREHENSIVE,
INTEGRATED
PLATFORM
PURPOSE-BUILT TO
SUPPORT THE
SYSTEMS,
WORKFLOWS, AND
PROCESSES OF
VIRTUAL
TRIALS
LET'S LOOK AT THE
COMPANIES.....

6. FORX FOCUSES ON
DRUGGING KEY
MOLECULAR
TARGETS INVOLVED IN
DNA REPLICATION
STRESS, AS A
NEW APPROACH
TOWARDS THE
DEVELOPMENT OF
TARGETED
ANTICANCER DRUGS.
LET'S LOOK AT THE
COMPANIES.....

7. THE COMPANY IS
DEVELOPING A NOVEL
SET OF ENGINEERED
T-CELL
THERAPEUTICS THAT
TARGET
LOSS OF GENES IN
SOLID TUMORS.
LET'S LOOK AT THE
COMPANIES.....

8. THE COMPANY
IS CREATING LIFE-
CHANGING T CELL
THERAPIES FOR
PATIENTS BY
UNLEASHING THE
UNTAPPED POTENTIAL
OF THE HUMAN
IMMUNE SYSTEM.
LET'S LOOK AT THE
COMPANIES.....

9. THE COMPANY
IS DEVELOPING GENE
THERAPIES WITH THE
POTENTIAL TO
RESTORE, IMPROVE
AND PRESERVE HIGH-
ACUITY PHYSIOLOGIC
HEARING FOR PEOPLE
LIVING WITH
DISABLING HEARING
LOSS.
LET'S LOOK AT THE
COMPANIES.....

10. THE COMPANY IS
DEVELOPING NOVEL
CELL THERAPIES BY
COMBINING INSIGHTS
FROM REGULATORY T
CELL BIOLOGY AND
ANTIGEN RECEPTOR
ENGINEERING
LET'S LOOK AT THE
COMPANIES.....

11. FOLLOW ME FOR MORE...
@ROHIT-KUMAR-KANWER